



September 8, 2021

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of collaborative research agreement with NanoCarrier Co., Ltd. for development of a designer cell as reinforced cell therapy utilizing SHED

Tokyo, September 8, 2021 – Kidswell Bio Corporation (KWB) executed a collaborative research agreement with NanoCarrier Co., Ltd. (NanoCarrier) for the development of a gene transfer method with effective mRNA for SHED and verification of the effectiveness of gene transfer designer SHED by combining SHED with a gene delivery technology Nanomicelles owned by Nanocarrier.

If it leads to the establishment of an effective gene transfer method using mRNA into SHED, various genes can be conveniently introduced into cells, including SHED. KWB believes that this collaboration is expected further to strengthen cell functions or to create a designer SHED that has a proper gene optimal for a cure for specific diseases.

The impact on the business results for the fiscal year ending March 2022 is expected to be minimal.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which GTS has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED and CSC, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com